Structurally and functionally distinct early antibody responses predict COVID-19 disease trajectory and mRNA vaccine response
Chakraborty et al. (BioRxiv) doi: 10.1101/2021.05.25.445649
Mild COVID-19 patients who experienced a worsening disease trajectory were characterised by the absence of an early robust neutralising IgG response with elevations in both afucosylated anti-spike IgG and the CD16a receptor on myeloid cells, which contribute to the inflammatory phenotype.
IgG post-translational modifications are also associated with specific patient characteristics including sex, age, demographic features
The mouse model is not a model of COVID-19 pathogenesis
The authors did not discuss the impact of afucosylation on IgG confirmation and the potential link with their non-neutralising activity
The authors did not discuss the potential benefit to use selective blockades of CD16a
They demonstrated the functional link between afucosylated IgG and induction of lung inflammation in an in vivo model.
Elevated concentrations of afucosylated IgG could be included in a panel of predictive factors of worsening COVID-19.
Reviewed by Stephanie Longet as part of the cross-institutional journal club of the Immunology Institute of the Icahn School of Medicine, Mount Sinai, the Kennedy Institute of Rheumatology and the Oxford Centre for Immuno-Oncology (OXCIO) (University of Oxford, GB) and Karolinska Institute’s Center for Infectious Medicine (CIM) & Center for Molecular Medicine (CMM).